Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257322 · ClinicalTrials.gov registry record · Phase 2
Cellular Immune Augmentation in Colon and Rectal Cancer
A Phase 2 study of Colon Cancer and Rectal Cancer, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00257322 is a Phase 2 study of Colon Cancer and Rectal Cancer that has completed, run by University of California, Irvine. The registered enrollment target is 20 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00257322, a Phase 2 study of Colon Cancer and Rectal Cancer, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
While new treatments for metastatic and recurrent colorectal cancer have become available over the past several years, this disease remains incurable with a limited life expectancy from the time of diagnosis. New strategies for treatment of disseminated colorectal cancer are needed. Under this proposal, patients with advanced colorectal cancer will receive Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to stimulate endogenous dendritic cells and enhance anti-tumor immune mechanisms. This will be combined with standard chemotherapy and patients will be followed for response and overall survival. Detailed correlative laboratory analysis will also be performed to define the extent of dendritic cell and cellular immune system stimulation.
Conditions Studied
Interventions
- DRUG GM-CSF
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-04 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257322
The ClinicalTrials.gov registry entry for NCT00257322 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which GM-CSF is the first listed.
NCT00257322 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00257322 about?
NCT00257322 is a clinical study titled "Cellular Immune Augmentation in Colon and Rectal Cancer". While new treatments for metastatic and recurrent colorectal cancer have become available over the past several years, this disease remains incurable with a limited life expectancy from the time of diagnosis. New strategies for treatment of disseminated colorectal cancer are needed. Under this propo...
What is the current status of trial NCT00257322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-04. Estimated completion is 2007-01.
What conditions does trial NCT00257322 study?
This clinical trial studies the following conditions: Colon Cancer, Rectal Cancer.
What interventions are being tested in trial NCT00257322?
The interventions under investigation include: GM-CSF (DRUG).
Who is sponsoring clinical trial NCT00257322?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00257322 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
RECRUITING · Phase 2
-
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.